Illumina Inc (NASDAQ:ILMN)

CAPS Rating: 3 out of 5

The Company is a developer, manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function.

Results 1 - 20 of 92 : 1 2 3 4 5 Next »

Recs

0
Member Avatar 401ktimer1 (51.81) Submitted: 4/9/2014 4:25:11 PM : Outperform Start Price: $145.03 ILMN Score: -6.23

Leader in gene sequencing. A favorite of Fidelity funds:
http://news.investors.com/investing-mutual-funds/040814-696376-fidelity-trend-likes-health-and-tech-outlooks.htm?ref=SeeAlso

Recs

0
Member Avatar rivahrat (77.81) Submitted: 3/5/2014 1:14:40 PM : Outperform Start Price: $179.71 ILMN Score: -23.81

Rule Breaker in novel medical area of low cost DNA sequencing.

Recs

0
Member Avatar investisseuse (36.53) Submitted: 2/19/2014 7:29:06 PM : Outperform Start Price: $173.72 ILMN Score: -23.73

Genome sequencing for under a $1000. bucks? and China as a new customer? What's not to like?

Recs

0
Member Avatar SqwiiTrader (37.30) Submitted: 2/19/2014 4:50:18 PM : Underperform Start Price: $173.72 ILMN Score: +23.73

Too far too fast ,, near weekly demark 13 sell

Recs

0
Member Avatar bradrimm (21.37) Submitted: 2/9/2014 9:58:08 AM : Outperform Start Price: $157.03 ILMN Score: -17.47

Genome sequencing will lead the future of healthcare, education, statistics and many other social trends... the question is whether its too early to blossom..

Recs

0
Member Avatar 1russianguy (61.77) Submitted: 2/4/2014 12:14:09 PM : Outperform Start Price: $151.06 ILMN Score: -16.55

Bill Gunderson long.

Recs

0
Member Avatar otherAquanaut (99.79) Submitted: 1/31/2014 10:24:53 AM : Outperform Start Price: $150.71 ILMN Score: -15.21

Currently leading the way in pressing down the cost of genetic sequencing. That's a huge forward looking market.

Recs

0
Member Avatar gpag0nz (< 20) Submitted: 1/14/2014 2:23:45 PM : Outperform Start Price: $120.72 ILMN Score: +10.58

Outstanding performance, takeover potential

Recs

0
Member Avatar Ctheu1 (< 20) Submitted: 12/4/2013 7:09:41 PM : Outperform Start Price: $97.40 ILMN Score: +35.18

Great New DNA company. Its the Apple of DNA.

Recs

0
Member Avatar stereotyp72 (83.02) Submitted: 10/22/2013 12:27:45 PM : Outperform Start Price: $88.62 ILMN Score: +46.52

http://www.nasdaq.com/symbol/ilmn/short-interest

Recs

0
Member Avatar Investatech (< 20) Submitted: 10/21/2013 6:44:01 PM : Outperform Start Price: $86.50 ILMN Score: +50.03

Market segment eager and this has the foundation to traverse all green sectors.

Recs

1
Member Avatar drb1000 (50.01) Submitted: 9/9/2013 12:53:30 PM : Outperform Start Price: $80.19 ILMN Score: +57.41

A reliable popular DNA sequencing technology and a critical eye on staying competitive.

Recs

0
Member Avatar Raphael1990 (96.98) Submitted: 2/24/2013 12:28:15 PM : Underperform Start Price: $49.03 ILMN Score: -154.14

Takeover is off the table for now, but the valuation is still too high given the fundamentals.

Recs

2
Member Avatar MrNonsensical (80.35) Submitted: 10/17/2012 3:08:50 PM : Outperform Start Price: $47.93 ILMN Score: +155.14

I recently conducted a series of interviews with a group of Chinese doctors, top-shelf people at the peak of their profession.

When I asked them what the biggest medicinal breakthroughs of the foreseeable future will be, almost all of them replied, "personalized care based on DNA."

Given this specialized guidance from a flock of well-informed geniuses, I think it's wise to buy and hold shares -- a lot of them -- of the company that has a stranglehold on DNA sequencing technology.

Recs

4
Member Avatar slycat910 (69.26) Submitted: 8/4/2012 10:27:56 PM : Outperform Start Price: $42.03 ILMN Score: +188.87

Very interesting company for a long run buy. Great prospects as a company. Genome sequencing will only become more popular over the next few years and Ilumina is the leader in this field. As they make advances in this field driving down the price it will become more affordable to everyday people and soon be an essential part of modern healthcare as genome sequencing can be very useful as a preventative measure for almost all major illnesses.

Recs

1
Member Avatar HIGHG33K (73.71) Submitted: 7/9/2012 3:33:53 PM : Outperform Start Price: $40.63 ILMN Score: +195.44

A takeover target.

Recs

1
Member Avatar FWWright (< 20) Submitted: 6/14/2012 11:24:05 PM : Outperform Start Price: $39.25 ILMN Score: +205.35

I am a believer in personalized medicine (think DNDN -- not a great stock so far, but a great approach to a difficult cancer) - diagnosis of problems (and treatments) through (increasingly cheap) DNA mapping is the future. I am not sure if ILMN is better than LIFE (or possibly AFFX) but it is a great company with great prospects. The reason for my 2-4 year timeframe is that I think it will be bought by a bigger firm.

Recs

0
Member Avatar CKRhea12 (< 20) Submitted: 2/26/2012 8:22:53 PM : Outperform Start Price: $51.00 ILMN Score: +128.56

Although largely dependent on the research arena (heavily dependent on state funding) currently, genomic sequencing is beginning to make its way into the clinical setting and is being used by pharmaceuticals to help find biomakers for monoclonal antibody development. This transition will be slow progress at first, but will quickly pick up as clinical applications are supported with mAbs directed at specific biomarkers from the genotyping.

Recs

0
Member Avatar drrtc2 (< 20) Submitted: 1/3/2012 7:06:12 PM : Outperform Start Price: $31.91 ILMN Score: +277.94

What a gift to give to your kids for Christmas--their very own genome. This is better than a car!

Recs

0
Member Avatar TopAustrianFool (81.17) Submitted: 10/11/2011 9:51:38 AM : Underperform Start Price: $26.18 ILMN Score: -360.63

"It appears that production got ahead of demand, though we won't know more about this until the company releases results later this month."

This is exactly what happens with Boom and Bust cycles. What the Fed did in 2009 to stimulate the economy caused a lot of companies to invest in longer term production and now with the end of QE there is a lot of downsizing a liquidation. Investors don't know which companies will survive liquidation and which will go bust, so they are pulling a lot of their money out of the market.

ILMN with their connection to research and academia is the typical company to which stimulus dollars went. I know because I am connected to academia and I work on research, and I saw a lot of scrambling then to hire and increase capacity in order to spend stimulus dollars. Now the stimuls is gone and the economy is not growing. Add to that the coming cuts and you have a recipe for liquidation.

So the main question is the following. What is ILMN's ability to adapt, liquidate and downsize? That depends in how much debt they have and how much cash they have. If you can answer these questions, you will know if this is a hold or a sell.

Put in this category all the alternative energy companies. The ones making solar panels, bateries, windmills, etc.

Results 1 - 20 of 92 : 1 2 3 4 5 Next »

Featured Broker Partners


Advertisement